Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Sell at StockNews.com

Pulse Biosciences (NASDAQ:PLSE) was upgraded by stock analysts at StockNews.com to a “sell” rating in a research report issued on Thursday.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE opened at $17.41 on Thursday. The business has a fifty day moving average of $18.03 and a 200-day moving average of $16.89. Pulse Biosciences has a twelve month low of $6.59 and a twelve month high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter in the previous year, the business posted ($0.19) EPS.

Insiders Place Their Bets

In related news, CEO Burke Thomas Barrett sold 50,000 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $17.42, for a total value of $871,000.00. Following the completion of the sale, the chief executive officer now owns 63,172 shares in the company, valued at $1,100,456.24. This represents a 44.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert W. Duggan bought 55,256 shares of Pulse Biosciences stock in a transaction on Friday, December 13th. The shares were acquired at an average price of $17.18 per share, for a total transaction of $949,298.08. Following the completion of the acquisition, the director now owns 42,328,717 shares of the company’s stock, valued at approximately $727,207,358.06. This represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 71.50% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC bought a new stake in shares of Pulse Biosciences in the second quarter valued at about $91,000. Rhumbline Advisers lifted its stake in Pulse Biosciences by 6.7% in the 2nd quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock valued at $288,000 after acquiring an additional 1,608 shares in the last quarter. Franklin Resources Inc. acquired a new position in Pulse Biosciences during the 3rd quarter worth approximately $378,000. Creative Planning boosted its position in Pulse Biosciences by 113.9% during the 3rd quarter. Creative Planning now owns 21,910 shares of the company’s stock worth $384,000 after acquiring an additional 11,667 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company’s stock worth $530,000 after acquiring an additional 23,738 shares in the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.